Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $84 | $194 | $196 | $230 |
| - Cash | $58 | $79 | $84 | $140 |
| + Debt | $60 | $61 | $62 | $62 |
| Enterprise Value | $86 | $175 | $175 | $153 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 27.7% |
| EBITDA | -$5 | -$22 | -$2 | -$63 |
| % Margin | – | – | – | -16,263.2% |
| Net Income | -$6 | -$23 | -$4 | -$64 |
| % Margin | – | – | – | -16,679.8% |
| EPS Diluted | -0.16 | -0.59 | -0.095 | -2.18 |
| % Growth | 72.9% | -520.4% | 95.6% | – |
| Operating Cash Flow | -$21 | -$30 | -$31 | -$19 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$21 | -$30 | -$31 | -$19 |